Lexaria Shares Are Trading Higher On Completion Of Antiviral Drug Molecular Characterization Study

  • Lexaria Bioscience Corp LEXX has announced results from its antiviral drug molecular characterization study VIRAL-MC21-1, completed by Canada's federally funded research organization, the National Research Council (NRC).
  • The NRC has confirmed Lexaria's study objectives, demonstrating DehydraTECH processing and formulation technology does not create a covalently bonded new molecular entity. 
  • Each drug tested remained stable and did not undergo a change in chemical structure. 
  • The five drugs studied were remdesivir, ebastine, bepridil, rupintrivir, and colchicine.
  • These findings support accelerated regulatory filings authorizations of prospective DehydraTECH-enabled, repurposed antiviral drugs. 
  • The Company will pursue collaboration opportunities with pharmaceutical partners to incorporate DehydraTECH technology with antiviral drugs, including or similar to those currently being investigated.
  • Price Action: LEXX shares are up 9.5% at $7.3 during the premarket session on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!